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S214 Oral Presentationscomplications. We reports here 33 Korean PNH patients who un-
derwent allotransplantation.
Aims: To understand the impact of allotransplant in Korean PNH
patients, we retrospectively analyzed medical charts of 33 PNH pa-
tients from national registry in Korea.
Results: Patient ages ranged from 15 to 56 years (median 29 years,
male 14, female 19). Classic PNH were 12 patients and PNH with
bone marrow disease were 21. Median LDH level at the time of di-
agnosis was 1159 IU/L (297  7699). The source of stem cells were
bone marrow in 13 patients and peripheral blood in 20 patients. Sib-
ling donor were 23 and unrelated donor were 10. Conditioning reg-
imens consisted of BuCy or Cy/TBI (n5 14), fludarabine containing
reduced intensity regimen (n 5 18), or other. All patients attained
successful leukocyte engraftment (median 13 days, range 1030
days) and platelet engraftment (median 17 days, range 1148
days). Grade IIIV acute GVHD were in 19 patients (skin 13, liver
3, gut 3). Grade IIIV chronic GVHD were in 13 patients (limited
10, extensive 3). With a median follow-up of 82.6 months (range,
19.5 160.2 months), 26 patients are alive with CR. Seven patients
were died after transplantation due to pulmonary hemorrhage (n 5
2), sepsis (n 5 2), GVHD/multi organ failure n 5 2), or massive
thromboembolism (n 5 1). Patients with reduced intensity condi-
tioning regimen had a better survival than patients with conventional
conditioning regimen (p 5 0.027). There were no survival differ-
ences between classic PNH patients and PNH patients with BMD.
There were also no differences between two groups categorized by
PNH clone sizes, stem cell sources, and PNH related symptoms.
Conclusion: Our data demonstrates that reduced intensity condi-
tioning regimen is suitable for allogeneic stem cell transplatation
of PNH patients.31
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Nonmyeloablative conditioning with fludarabine (Flu) and 2 Gy
TBI with MMF/CSP postgrafting immunosuppression results in
reliable allogeneic engraftment. A retrospective analysis of pts
conditioned with 2 Gy TBI alone prior to receiving PBSC from
HLA-matched related donors showed that rejection primarily oc-
curred in pts who pre-HCT had not received intensive chemother-
apy. Addition of Flu (30 mg/m2/d x 3 d) in a subsequent cohort
seemed associated with increased nonrelapse mortality (NRM).
Here, we report results of a phase III randomized multi-institutional
trial that asked whether Flu was needed in heavily pretreated pts to
assure sustained engraftment of HLA-matched related grafts.
Immunosuppression included MMF (28 d) and CSP (180 d).
Eighty-five pts with AML (n 5 15), NHL (n 5 32), MM (n 5 9),
CLL (n 5 9), MDS (n 5 4), and HL (n 5 16) were randomized to
be conditioned with either 2 Gy TBI alone (TBI; n 5 44) or Flu/
2 Gy TBI (Flu/TBI; n5 41) with stratification by transplant center,
disease risk and prior high dose HCT. Pts received G-PBMC con-
taining a median of 7.9 x106 CD34 and 3.6 x108 CD3 cells/kg.
The median age was 55 (range, 17–73) years. Forty-five had failed
previous autologous (n 5 41) or allogeneic (n 5 4) high-dose
HCT. The primary endpoint was NRM with secondary endpoints
of survival, relapse/progression, GHVD and rejection. Median
follow-up was 4.6 (range, 0.6–7) years.Table. Transplant outcomes after HLA-matched related do-
nor HCT in patients conditioned with 2 Gy TBI only or with
fludarabine 90 mg/m2
TBI Flu/TBI(n 5 44) (n 5 41) PRejections (number of pts) 2 0 0.50GVHD Grade II-IV acute @ 120 d, % 34 46 0.23Grade III-IV acute @ 120 d, % 9 7 0.82Chronic @ 3 years 49 71 0.21Donor
chimerismT-cell day 28, %, median 61 90 <0.0001T-cell day 84, %, median 68 92 <0.0001NK-cell day 28, %, median 75 96 0.0005Nonrelapse mortality @ 3 years, % 17 14 0.35Relapse/progression @ 3 years, % 51 33 0.04Relapse mortality @ 3 years, % 32 22 0.10Overall survival @ 3 years, % 52 65 0.09Progression-free survival @ 3 years, % 32 53 0.03No significant differences between arms were observed for NRM
(3 year; TBI 17%, Flu/TBI 14%), grade II-IV acute (TBI 34%, Flu/
TBI 46%) or chronic GVHD (TBI 49%, Flu/TBI 71%). Rejection
was only observed in 2 TBI pts. The 3 year survival was 52% and
65% in TBI and Flu/TBI pts (p 5 0.09), respectively, with a higher
incidence of relapse/progression (TBI 51%, Flu/TBI 33%, p5 0.04)
and relapse related mortality (TBI 32%, Flu/TBI 22%, p 5 0.10),
translating into a significantly lower progression-free survival (TBI
32%, Flu/TBI 53%, p 5 0.03) in TBI pts. Compared to TBI pts,
the CD3 donor chimerisms on d28 and d84 were significantly higher
in Flu/TBI pts as was the NK cell chimerism on d28. Even though
low rates of rejection and similar incidences of NRM were observed
in both arms, Flu/TBI pts had better progression free survival. In
view of the significantly higher CD3 and NK donor chimerism in
Flu/TBI pts, the result of this randomized trial demonstrate the im-
portance of Flu in augmenting the graft versus tumor effect, by en-
suring prompt and durable high level donor engraftment early
post-transplant.
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Background: Invasive ADV infections are a known cause of mortal-
ity in HSCT.High or rising ADV viral loads are thought to be a pre-
dictor of ADV disease. T-cell depletion (TCD) reduces the risk of
graft vs host disease, but has been associated with an increased inci-
dence and complications of certain viral infections.We examined the
outcomes of patients found to have ADV viremia after TCDHSCT
at our institution.
Method: A retrospective review was conducted on 401 adult and pe-
diatric patients who received TCD HSCTs at MSKCC from Jan
2006 through March 2011. Follow up ranged from (6 months - 5
years). Quantitative ADV PCR in whole blood was evaluated by
the treating physicians based on clinical symptoms. ADV viremia
was defined as at least 1 positive study of $ 1,000 copies/ml or .2
consecutive positive studies of $500 copies/ml/ ADV PCR. Defini-
tions were: early ADV viremia - first positive ADV PCR at\ 180
days post HSCT, and high viral load (HVL) as $ 10,000 copies/
ml. ADV Disease: Definite: presence of typical adenovirus nuclear
inclusions on histopathology, and/or positive culture from sterile
site (other than blood), or both. Probable adenovirus: ADV viremia
and associated clinical symptoms without other identifiable causes).
Results: The 401 TCD HSCTs included 23.7% children, 90% pe-
ripheral blood stem cell grafts, and 63.1% unrelated donors, median
age 47.5 yrs (range 0.1-73 yrs). Thirty five (8.7%) patients were di-
agnosed with ADV viremia at a median of 93 days (range 15 - 674)
post HSCT. The incidence of diagnosed ADV viremia in this group
was higher in pediatric vs adult pts (15.3 vs 6.2%). ADVwas detected
in 35/401 (8.7%) (6.2% adult and 15.3% pediatric) pts a median of
